XML 108 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Stockholders' Equity - USD ($)
Total
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (shares) at Dec. 31, 2016   23 74,062,370        
Beginning balance at Dec. 31, 2016 $ 123,378,420 $ 0 $ 74,062 $ 556,718,356 $ (434,838,235) $ 1,327,968 $ 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (shares)     15,437,406        
Issuance of common stock for cash, net of financing costs of $4.9 million 94,347,922   $ 15,437 94,332,485      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     857,868        
Exercise of stock options for cash and vesting of RSUs, net of tax payments 1,342,250   $ 859 1,341,391      
Stock-based compensation 13,070,962     13,070,962      
Net loss attributable to common stockholders (88,205,772)       (88,205,772)    
Unrealized gain on short-term investments, net of tax 7,458         7,458  
Unrealized loss on investment in affiliated entity, net of tax (1,452,431)         (1,452,431)  
Ending balance (shares) at Dec. 31, 2017   23 90,357,644        
Ending balance at Dec. 31, 2017 142,488,809 $ 0 $ 90,358 665,775,504 (523,356,317) (117,005) 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (shares)     5,669,025        
Issuance of common stock for cash, net of financing costs of $4.9 million 29,227,776   $ 5,669 29,222,107      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     1,199,141        
Exercise of stock options for cash and vesting of RSUs, net of tax payments 1,809,526   $ 1,199 1,808,327      
Stock-based compensation 10,654,622     10,988,277 (333,655)    
Net loss attributable to common stockholders (96,967,830)       (96,967,830)    
Unrealized gain on short-term investments, net of tax (180,496)         (180,496)  
Unrealized loss on investment in affiliated entity, net of tax 0            
Ending balance (shares) at Dec. 31, 2018   23 97,225,810        
Ending balance at Dec. 31, 2018 87,032,407 $ 0 $ 97,226 707,794,215 (620,426,436) (528,867) 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (shares)     3,340,678        
Issuance of common stock for cash, net of financing costs of $4.9 million 9,089,009   $ 3,340 9,085,669      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     794,546        
Exercise of stock options for cash and vesting of RSUs, net of tax payments (780,405)   $ 795 (781,200)      
Equity component of issuance of convertible notes 15,752,698     15,752,698      
Stock-based compensation 10,901,320     10,795,403     105,917
Acquisition of non-controlling interest in Geneos, net 2,960,131           2,960,131
Net loss attributable to common stockholders (120,551,777)       (119,359,219)   (1,192,558)
Unrealized gain on short-term investments, net of tax 1,001,475         1,001,475  
Unrealized loss on investment in affiliated entity, net of tax 0            
Ending balance (shares) at Dec. 31, 2019   23 101,361,034        
Ending balance at Dec. 31, 2019 $ 5,404,858 $ 0 $ 101,361 $ 742,646,785 $ (739,785,655) $ 472,608 $ 1,969,759